Morningside Venture Partners

Type

Venture Capital

Status

Active

Location

New York, United States

Total investments

38

Average round size

22M

Portfolio companies

25

Rounds per year

6.33

Lead investments

5

Follow on index

0.18

Exits

6

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyInternetSoftwareArtificial IntelligenceMachine LearningHealth CareMedical DeviceMedicalPharmaceuticalTherapeutics

Summary

Morningside Venture Partners appeared to be the VC, which was created in 1986. The main department of described VC is located in the Shanghai. The venture was found in Asia in China.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Morningside Venture Partners, startups are often financed by Providence Investment Company Limited, Nesta Ventures, UK Innovation & Science Seed Fund. The meaningful sponsors for the fund in investment in the same round are Providence Investment Company Limited, Takeda Ventures, Nesta Ventures. In the next rounds fund is usually obtained by Providence Investment Company Limited, Temasek Holdings, Takeda Ventures.

This organization was formed by Ronnie Chan. The overall number of key employees were 1.

Among the most popular portfolio startups of the fund, we may highlight Xiaomi, ENYO Pharma, Milk and Eggs. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low.

This Morningside Venture Partners works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. The fund is generally included in less than 2 deals every year. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2019. The typical startup value when the investment from Morningside Venture Partners is 10-50 millions dollars.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Geo focus
ChinaUnited Kingdom

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
38
Lead investments
5
Exits
6
Rounds per year
6.33
Follow on index
0.18
Investments by industry
  • Biotechnology (15)
  • Medical (11)
  • Therapeutics (8)
  • Health Care (8)
  • Software (6)
  • Show 34 more
Investments by region
  • United States (12)
  • China (10)
  • United Kingdom (7)
  • Russia (2)
Peak activity year
2018
Number of Unicorns
2
Number of Decacorns
3
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
1B
Group Appearance index
0.92
Strategy success index
0.20

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
VaxEquity 17 Jun 2020 Biotechnology, Medical, Therapeutics Seed United States, Massachusetts, Cambridge
Wantu 31 Oct 2014 Early Stage Venture 108K Shanghai, China

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.